Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Lancet (London, England)（2023）
摘要
F Hoffmann-La Roche and Exelixis.
更多查看译文
关键词
cabozantinib monotherapy,renal cell carcinoma,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要